Orthocell (ASX:OCC) announced a milestone in the US rollout of its flagship nerve repair product, Remplir, with the appointment of 12 distributors now covering 21 states.
This achievement surpasses the company's initial target of 10 distributors by June, reflecting strong demand and confidence in the product.
The distributors, all experienced specialists in nerve repair, will leverage established relationships with surgeons and hospitals to drive market penetration.
The expansion of Orthocell's distributor network follows the receipt of US FDA 510(k) clearance for Remplir in April and is a testament to the product's quality and the distributors' ability to generate strong sales in the $1.6 billion nerve repair market.
The rapid appointment of distributors is expected to boost revenue for the company moving forward.
Orthocell’s in-house sales, marketing, and medical affairs teams are supporting this rollout, with internal resources focused on training sales representatives, expanding relationships with key opinion leaders, and submitting proposals to hospitals.
Remplir is a collagen wrap designed to improve outcomes in nerve repair surgery and is already approved for sale in Australia, New Zealand, Thailand, and Canada, with additional regulatory submissions for the EU and UK expected within the next 6-12 months.